Cadila Pharmaceuticals Collaboration

Cadila Pharmaceuticals

In 2009, Novavax formed a joint venture with Cadila Pharmaceuticals Ltd., Ahmedabad, India, to develop, manufacture and market vaccines, pharmaceuticals and diagnostic products in India. This joint venture, called CPL-Biologics or CPLB, is developing a number of Novavax’ VLP vaccine candidates, as well as a number of Cadila’s therapeutic vaccine candidates for the Indian territory. Over the last decade Cadila Pharmaceuticals has focused on novel approaches to cancer management and is the first Indian company to get multiple investigational new drug applications (INDs) approved by U.S. Food and Drug Administration.